Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases.
about
Existing data sources for clinical epidemiology: Scandinavian Cohort for osteonecrosis of the jaw - work in progress and challenges.Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapyPrognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma.Tissue slice grafts of human renal cell carcinoma: an authentic preclinical model with high engraftment rate and metastatic potential.Development of a realistic in vivo bone metastasis model of human renal cell carcinomaDiagnosis, treatment, and follow-up of medullary thyroid carcinoma: recommendations by the Thyroid Department of the Brazilian Society of Endocrinology and Metabolism.Is administration of trastuzumab an independent risk factor for developing osteonecrosis of the jaw among metastatic breast cancer patients under zoledronic acid treatment?A rare case of osteonecrosis of the jaw related to imatinibRANK/OPG ratio of expression in primary clear-cell renal cell carcinoma is associated with bone metastasis and prognosis in patients treated with anti-VEGFR-TKIsCD98hc (SLC3A2) drives integrin-dependent renal cancer cell behavior.Bisphosphonates enhance EGFR-TKIs efficacy in advanced NSCLC patients with EGFR activating mutation: A retrospective study.Zoledronic acid in genitourinary cancer.Bone-targeted therapies for elderly patients with renal cell carcinoma: current and future directions.Heterogeneous drug target expression as possible basis for different clinical and radiological response to the treatment of primary and metastatic renal cell carcinoma: suggestions from bench to bedside.Biological agents: what they are, how they affect oral health and how they can modulate oral healthcare.New cancer therapies and jaw necrosis.Risk factors for medication-related osteonecrosis of the jaws: A systematic review.Osteonecrosis of jaw beyond antiresorptive (bone-targeted) agents: new horizons in oncology.Bisphosphonates in patients with renal cell carcinoma and bone metastases: a sunitinib global expanded-access trial subanalysis.Osteonecrosis of the Jaws in Patient Received Bisphosphonates and Sunitinib Separately: A Case ReportMedication-related osteonecrosis of the jaws caused lethal sepsis in an edentulous patient with multiple systemic factors.Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumab.Incidence of medication-related osteonecrosis of the jaw in patients treated with both bone resorption inhibitors and vascular endothelial growth factor receptor tyrosine kinase inhibitors.Current Controversies on the Pathogenesis of Medication-Related Osteonecrosis of the Jaw.
P2860
Q30888611-ABBC7745-E216-49D2-A8FF-57CE315B4823Q34007924-02F34E95-8B51-4D40-BE0F-D990F1CA3014Q34090594-CB6081D6-0593-4103-BC3D-1AE5D942E04FQ35150788-40F1271F-45B1-44D4-936A-2E1F259044EBQ35154534-3935880B-1C74-41B4-AA6E-02237C52F7DCQ35396089-B6DF159A-4ED0-4CF6-85FC-BF97D22386FEQ35624101-2416DF7E-A5D1-4A6A-B4B8-F1D92228C58EQ36360226-67F1483F-CA48-4D62-A305-0A4C6367BCBEQ36750660-5D17EE73-C4F8-471E-920D-C4386A092CCCQ37427983-B8E2EE65-1432-48F1-8FF3-E018196B5F39Q37687011-D5688DC7-2D0C-4429-9218-EAFB87F0504AQ38101500-CF752208-80E9-47FB-88A7-25B9D114DF93Q38144897-CCA6A282-6F30-4062-8278-B5CA05FC42A8Q38171327-F436A292-C7B7-4B20-B842-4FD83584A70AQ38538490-66270E3E-6CAC-4CB3-8461-29E19F026368Q38584982-89FA1411-8D1B-4F63-83CA-C0355DA082E9Q38705715-056CF6FC-7BA6-403C-9C5E-A3BB98BDB818Q38807483-74FF63F3-05DD-425D-8120-23C372606763Q38990710-D8BB38FD-286B-4C8D-84CA-C80A759A5C45Q42269851-CE9BDF9A-B0AD-463C-8833-6AAAE93FBDFBQ42324262-DB6EC70E-61AC-487A-983A-88F038683A33Q47325841-71D5410E-078F-4DA7-8E27-CA6D7FC5BFECQ47672449-95373D58-324F-4510-A3CB-7C58307D7FCFQ54500167-231F69F5-B534-4A89-BEC3-402DD93FF20F
P2860
Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Concomitant oral tyrosine kina ...... arcinoma with bone metastases.
@ast
Concomitant oral tyrosine kina ...... arcinoma with bone metastases.
@en
type
label
Concomitant oral tyrosine kina ...... arcinoma with bone metastases.
@ast
Concomitant oral tyrosine kina ...... arcinoma with bone metastases.
@en
prefLabel
Concomitant oral tyrosine kina ...... arcinoma with bone metastases.
@ast
Concomitant oral tyrosine kina ...... arcinoma with bone metastases.
@en
P2093
P2860
P356
P1476
Concomitant oral tyrosine kina ...... carcinoma with bone metastases
@en
P2093
A Karadimou
H Van Poppel
P Schöffski
P2860
P2888
P304
P356
10.1038/BJC.2012.385
P407
P577
2012-11-01T00:00:00Z